Variable Hematoloji / Destekleyici Bakım

Pain Management in Hematology and Chemotherapy-Induced Nausea-Vomiting (CINV)

In hematologic patients, pain and nausea directly affect both quality of life and treatment adherence; inadequately controlled side effects can lead the patient to discontinue therapy. The most important principle in PAIN MANAGEMENT is to approach pain according to its CAUSE: pain from vascular occlusion in sickle cell crisis, bone pain in myeloma, mucositis pain, and chemotherapy-induced NEUROPATHIC pain require different treatments; neuropathic pain responds poorly to opioids and requires neuropathic agents.

There are two critical rules in SICKLE CELL PAIN CRISIS: (1) ANALGESIA SHOULD NOT BE DELAYED, and the goal is to administer the first dose shortly after presentation; (2) these patients are often wrongly labeled as 'drug-seeking' — this bias leads to delayed treatment and death, and the patient's self-reported pain intensity should be considered. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS should be used cautiously in thrombocytopenia and renal dysfunction, and avoided in patients with bleeding disorders.

The basic principle in NAUSEA-VOMITING is PREVENTION: CINV is a side effect that is difficult to treat once it occurs but easy to prevent, and prophylaxis is administered BEFORE CHEMOTHERAPY according to the EMETOGENIC RISK of the regimen.

A single bad experience can lead to ANTICIPATORY (expectation-related) VOMITING, which is resistant to medications.

Rapid management

PAIN: determine the cause first because treatment changes accordingly — SICKLE CELL painful crisis (vascular blockage), MYELOMA/bone lesion, MUCOSITIS, chemotherapy-related NEUROPATHIC pain (responds poorly to opioids, requires neuropathic agents), tumor pressure or infection.
DO NOT DELAY ANALGESIA IN SICKLE CELL CRISIS; the goal is to give the first dose shortly after admission, and the patient's reported pain intensity is taken as the basis — labeling these patients as “drug seekers” is a common bias that leads to fatal delays.
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS: be cautious or avoid in thrombocytopenia, renal dysfunction, and bleeding disorders.
New and severe BACK PAIN + neurological findings → SPINAL CORD COMPRESSION, is an emergency.
NAUSEA-VOMITING: the main principle is PREVENTION — prophylaxis is given BEFORE CHEMOTHERAPY according to the EMETOGENIC RISK of the regimen; once vomiting starts, control is difficult.
Acute (first 24 hours) and DELAYED (after 24 hours) phases should be addressed separately; the delayed phase is often neglected.
ANTICIPATORY NAUSEA arises from previous bad experience and is resistant to drugs; the best treatment is to achieve good control in the first cycle.
In patients with ongoing nausea, drug side effects, constipation, electrolyte imbalance, hypercalcemia, obstruction, and CENTRAL NERVOUS SYSTEM INVOLVEMENT should be excluded.

Drug	Adult	Pediatric	Route	Duration
Evaluation according to the cause of pain The source of pain in hematologic patients is very diverse, and each requires different treatment. The painful crisis in sickle cell disease is ischemic pain caused by occlusion of small vessels by sickled erythrocytes and requires rapid, adequate analgesia and hydration. Pain in multiple myeloma and bone metastases is due to bone destruction and benefits from radiotherapy and skeletal-related event preventive treatments. Mucositis pain arises from the direct effects of chemotherapy and radiotherapy on the mucosa; oral care and topical approaches are important. Chemotherapy-induced peripheral neuropathy, on the other hand, is a burning, tingling type of pain in a glove-and-stocking distribution; this pain responds poorly to opioids and requires agents targeting neuropathic pain. Therefore, the approach of 'there is pain, let's give an opioid' is both insufficient and causes unnecessary side effects. Additionally, newly arising pain may indicate an underlying complication (infection, fracture, cord compression, thrombosis) and its cause should be investigated.	The location, nature of pain (burning/tingling → neuropathic; deep/throbbing → bone or vascular blockage), intensity, duration, and accompanying findings are evaluated; intensity is measured by the PATIENT'S OWN REPORT	Age-appropriate pain scales (facial expression, behavior-based scales) are used in children	—	Repeated at each assessment
Analgesia in sickle cell painful crisis The biggest problem in the management of sickle cell painful crisis is not the choice of medication, it is DELAY. These patients can be kept waiting for long periods in emergency departments and their analgesia can be delayed; the most common reason for this is that they are labeled as 'drug-seeking' due to repeated visits and opioid requirements. This bias is both medically incorrect and harmful: a sickle cell crisis is an objective tissue ischemia condition, there is no laboratory test that indicates the severity of pain, and therefore the patient's self-report should be taken as the basis. Delay not only causes suffering; it leads to prolonged crises, missed life-threatening complications such as acute chest syndrome, and loss of the patient's trust in the healthcare system. Most of these patients know their crises well and know from previous experience which dose works; this knowledge is valuable and should be used. Preparing individualized pain plans in advance both accelerates treatment and prevents disputes (sickle cell protocols).	Analgesia is started WITHOUT DELAY; the goal is to administer the first dose shortly after presentation and to adjust the dose based on response. AGENT SELECTION AND DOSES are determined according to the patient’s previous crisis experience and institutional sickle cell protocol	The same urgency applies; doses are calculated according to body weight and verified against the pediatric protocol	IV / oral	During the crisis, doses are reduced according to response
Considerations in neuropathic pain and analgesic selection Hematologic patients have specific limitations in analgesic selection. Non-steroidal anti-inflammatory drugs increase bleeding risk in thrombocytopenic patients because they impair platelet function; additionally, they can affect kidney function, which is problematic in patients already under renal burden (myeloma, tumor lysis, nephrotoxic drugs). Therefore, their use should be evaluated individually and avoided in those with bleeding disorders. Paracetamol is commonly used but it should be kept in mind that it can mask fever in neutropenic patients. Opioids provide effective analgesia but cause constipation, and this side effect is particularly problematic in hematologic patients because straining in neutropenic patients can lead to anal fissures and infection; therefore, a laxative should be planned simultaneously when starting opioids. Additionally, intramuscular injections should be avoided in patients taking opioids due to the risk of hematoma in the presence of thrombocytopenia.	In chemotherapy-related neuropathic pain, neuropathic pain agents are used; opioids are less effective for this pain. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS should be carefully assessed or avoided in thrombocytopenia, renal dysfunction, and bleeding disorders. AGENT AND DOSES should be verified from institutional protocol	In children, agent selection and doses are determined according to the pediatric protocol	Oral / topical	According to the response
Prophylaxis for chemotherapy-induced nausea and vomiting The basic principle in chemotherapy-induced nausea and vomiting is prevention, which is significantly superior to therapeutic approaches. The reason is physiological: once the vomiting reflex is triggered, central mechanisms are activated and it becomes difficult to control. Therefore, antiemetic prophylaxis is given before chemotherapy starts and is selected according to the emetogenic risk of the regimen; giving high-risk prophylaxis for a low-risk regimen creates unnecessary drug load, whereas giving insufficient prophylaxis for a high-risk regimen inevitably leads to vomiting. A frequently neglected point is the DELAYED phase: with some drugs, nausea appears after the first 24 hours and occurs at home after the patient is discharged; if this period is not covered, the patient feels comfortable on the first day but worsens in the following days. The adequacy of prophylaxis should be evaluated after each cycle and intensified if necessary for the next cycle.	Prophylaxis is determined according to the EMETOGENIC RISK of the REGIMEN (high/moderate/low/minimal) and is given BEFORE CHEMOTHERAPY; ACUTE (first 24 hours) and DELAYED (after 24 hours) periods should be covered separately. AGENT COMBINATIONS AND DOSES should be verified from the institutional oncology protocol	In children, emetogenic risk classification and doses are determined according to the pediatric protocol	IV / oral	It is started before chemotherapy and continued to cover the delayed period
Differential evaluation in patients with ongoing nausea Not every nausea in a patient undergoing chemotherapy is related to chemotherapy, and assuming so can lead to dangerous diagnostic delays. Constipation is a very common cause of nausea, especially in patients using opioids, and it can be identified with a simple inquiry. Hypercalcemia causes nausea in patients with myeloma and bone involvement, along with constipation and changes in consciousness; it is treatable and should not be overlooked. Electrolyte disturbances, kidney and liver dysfunction, other medications used (especially antibiotics and opioids), and infections also lead to nausea. A particularly warning sign is nausea that worsens in the morning, accompanied by headache and neurological findings; this condition suggests increased intracranial pressure and central nervous system involvement and requires urgent imaging. Therefore, in nausea that persists despite prophylaxis, the cause should be reassessed before increasing antiemetic therapy.	In nausea persisting despite prophylaxis: drug side effects, CONSTIPATION, electrolyte disturbances, HYPERCALCEMIA, kidney and liver dysfunction, gastrointestinal OBSTRUCTION, infection, increased intracranial pressure, and CENTRAL NERVOUS SYSTEM INVOLVEMENT should be evaluated	Same framework; in children, dehydration risk develops more rapidly	—	Diagnostic evaluation

Alternative

Pre-preparation of patient-specific written pain plans for patients with sickle cell disease accelerates treatment in the emergency department and prevents unnecessary disputes; the patient should carry their own plan.
Patient-controlled analgesia provides effective control in selected patients with recurrent and severe pain and reduces the gaps between dose intervals.
For bone pain, radiotherapy, skeletal-related event preventive treatments, and surgical stabilization when necessary are considered.
In mucositis pain, oral care, topical approaches, and nutritional support are an integral part of drug therapy.
Non-drug methods (warm application, relaxation techniques, psychological support) are helpful as complementary measures in pain and nausea management; behavioral approaches are especially prioritized in anticipatory vomiting.
Anxiolytic agents and behavioral methods are used in anticipatory vomiting; however, the most effective approach is to prevent this condition by providing full control during the first cycle.
In refractory nausea, combining agents with different mechanisms of action and adding options such as olanzapine are evaluated according to institutional protocol.

Red flags

DELAYING ANALGESIA in sickle cell pain crises or labeling the patient as 'drug-seeking' → is a common, harmful, and potentially fatal bias; the pain severity reported by the patient should be the basis.
Chest pain, fever, hypoxia, and new lung infiltrate in a sickle cell patient → ACUTE CHEST SYNDROME; should not be monitored as a pain crisis, requires emergency evaluation (relevant protocol).
Newly onset severe BACK PAIN + weakness in legs, sensory loss, or bladder-bowel dysfunction → SPINAL CORD COMPRESSION; requires urgent imaging and treatment.
Use of NON-STEROIDAL ANTI-INFLAMMATORY DRUG in a patient with thrombocytopenia or bleeding disorder → increases bleeding risk; may also impair kidney function.
INTRAMUSCULAR INJECTION in a thrombocytopenic patient → risk of hematoma; alternative routes should be preferred.
Not planning a LAXATIVE in a patient started on opioids → constipation; straining in neutropenic patients opens a portal for anal fissure infection.
Attempting to treat neuropathic pain with opioids → inadequate control and unnecessary side effects; neuropathic agents are needed.
Increasing antiemetic without investigating the cause in persistent nausea despite prophylaxis → HYPERCALCEMIA, constipation, obstruction, and CENTRAL NERVOUS SYSTEM involvement can be overlooked.
Morning worsening nausea + headache + neurological finding → increased intracranial pressure and central nervous system involvement; urgent imaging is required.
Inadequate antiemetic prophylaxis during the first course → ANTICIPATORY VOMITING develops and this condition is drug-resistant.

Disposition and follow-up

Green zone: Mild-moderate pain or nausea manageable outpatient, responsive to oral treatment: outpatient follow-up, written treatment plan, concurrent laxative plan, control appointment, and provision of criteria for seeking care.
Yellow zone: Pain or nausea unresponsive to oral treatment, dehydration, inadequate oral intake, diagnostic uncertainty: hospitalization or observation, parenteral treatment, fluid-electrolyte correction, reassessment of cause.
Red zone: Acute chest syndrome, spinal cord compression, increased intracranial pressure, severe dehydration with electrolyte imbalance, uncontrollable severe pain: urgent hospital admission, immediate imaging and treatment, joint management with relevant specialties.

Key clinical points

READ FIRST — delay and bias in sickle cell crisis.

DELAYING ANALGESIA: the goal is to give the first dose in a SHORT TIME after presentation | THERE IS NO LABORATORY TEST that shows the intensity of pain → the patient's SELF-REPORT is taken as the basis | Labeling these patients as "DRUG SEEKERS" is common, wrong, and a bias that leads to FATAL delays | The patient usually KNOWS their own crisis and the dose that works

Sickle cell painful crisis is one of the best-documented examples in medicine where bias directly turns into harm. These patients frequently visit the emergency department due to recurrent crises throughout their lives and regularly require opioids; these two characteristics can be misinterpreted as addiction or drug-seeking. However, there is objective tissue ischemia underlying the crisis, and since there is no laboratory test to measure this ischemia, the severity of pain can only be assessed by the patient's report. The cost of delay is high: until pain is controlled, the crisis prolongs, the patient remains immobile, and hypoventilation develops; this increases the risk of acute chest syndrome. Additionally, the patient's trust in the healthcare system is damaged and subsequent visits are delayed, leading to late recognition of potentially fatal complications. The practical solution is to prepare patient-specific written pain plans in advance; these plans both speed up treatment and prevent repeated discussions at each visit. Knowing what worked in the patient's previous crises is valuable information and should be taken into account.

READ FIRST — prevention is superior to treatment in nausea

Prophylaxis is given BEFORE CHEMOTHERAPY according to the EMETOGENIC RISK of the REGIMEN (high/medium/low/minimal) | The ACUTE phase (first 24 hours) and DELAYED phase (after 24 hours) should be covered SEPARATELY — the delayed phase is often NEGLECTED and occurs while the patient is at home | Once vomiting starts, control becomes DIFFICULT

The superiority of prevention over treatment in nausea and vomiting management is based on a physiological rationale: once the vomiting reflex is triggered, central mechanisms come into play, and controlling it from that point onward is both more difficult and requires higher doses. For this reason, antiemetics are administered before chemotherapy begins. Selecting prophylaxis according to the emetogenic risk of the regimen prevents a twofold error: giving multiple antiemetics to a minimal-risk regimen creates unnecessary side effects and costs; approaching a high-risk regimen with a single agent inevitably leads to vomiting. The most frequently overlooked point is the delayed phase; with some agents, nausea becomes pronounced not on the first day but in the following days, when the patient is at home. If this period is not covered, the patient feels fine in the hospital, suffers at home, and comes to the next cycle in fear. Therefore, after each cycle, questions such as 'how many days and how much nausea did you have?' should be asked, and prophylaxis should be strengthened accordingly.

READ FIRST — anticipatory (expectation-related) vomiting

Arises from BAD EXPERIENCE during previous cycles; even the smell of the hospital, seeing the nurse, or approaching the hospital can trigger it | It is a classic CONDITIONING response → RESISTANT TO ANTIEMETIC DRUGS | BEST TREATMENT IS PREVENTION: achieve full control in the first cycle | Once developed, behavioral methods and anxiolytics are used

Anticipatory vomiting is one of the most instructive side effects of chemotherapy because it is caused by learning, not by the drug. The patient learns to associate vomiting with the chemotherapy environment; this is a clinical example of classical conditioning. Once established, the trigger is no longer the drug itself but the stimuli accompanying it: the smell of the hospital, the appearance of the treatment room, or even the arrival of the appointment day. For this reason, antiemetic drugs do not show the expected effect in this scenario; the issue is not in the chemoreceptor zone but is a learned response. The practical conclusion is very clear: the most effective treatment for anticipatory vomiting is to fully control nausea in the first cycle, preventing this conditioning from ever occurring. That is, the adequacy of prophylaxis in the first cycle determines not only that day but the entire treatment process. Once the condition is established, behavioral methods (relaxation techniques, systematic desensitization) and anxiolytic agents are used, but the response may be limited.

The nature of the pain determines the treatment.

BURNING, tingling, glove-sock distribution → NEUROPATHIC (chemotherapy-induced) → WEAK RESPONSE TO OPIOIDS, a neuropathic agent is needed | Deep, throbbing, localized in bone → bone lesion → radiotherapy and skeletal protective treatments | Widespread, crisis-like → sickle cell vascular occlusion | Burning in mouth/throat → MUCOSITIS

Classifying pain according to its cause gives better results than the reflex of 'there is pain, let's give an analgesic' because each type of pain arises from a different mechanism and responds to different drugs. Neuropathic pain originates from nerve damage and cannot be sufficiently suppressed through opioid receptors; therefore, increasing the opioid dose does not control the pain but increases side effects. Bone pain originates from a local destruction process, and treatments targeting this process (radiotherapy, skeletal-related event preventive agents) provide more lasting benefit than analgesics. Pain in a sickle cell crisis is ischemic and requires rapid, adequate systemic analgesia along with supportive measures. Mucositis pain is local, and oral care with topical approaches is prioritized. Additionally, newly emerging or qualitatively changing pain always signifies a new question: fracture, infection, thrombosis, or cord compression? Simply increasing the dose without asking this question masks the underlying complication.

Limits of analgesic selection in hematologic patients

NON-STEROIDAL ANTI-INFLAMMATORY DRUGS: impair platelet function (AVOID in thrombocytopenia and bleeding disorders), may impair kidney function | PARACETAMOL: may MASK FEVER in neutropenic patients | OPIOID: causes constipation → PLAN LAXATIVE CONCOMITANTLY (in neutropenia, straining is a portal for anal fissure infection) | AVOID INTRAMUSCULAR INJECTION in thrombocytopenia

The choice of analgesics in hematologic patients carries restrictions different from the general population, and when these restrictions are unknown, a well-intentioned prescription can cause harm. Nonsteroidal anti-inflammatory drugs impair platelet function either irreversibly or temporarily; in a patient whose platelet count is already low, this significantly increases the risk of bleeding. The same drugs reduce renal blood flow, endangering kidneys that are already under stress due to myeloma or tumor lysis. Paracetamol is a safe option, but in neutropenic patients, regular use can suppress fever and delay the recognition of febrile neutropenia; therefore, fever monitoring should be emphasized during the neutropenic period. The constipation side effect of opioids is not a common discomfort in hematologic patients: in a neutropenic patient, straining can cause an anal fissure, which becomes a gateway for the gut flora to enter the bloodstream. Therefore, a laxative should be planned concurrently when starting opioids. Intramuscular injections should be avoided in thrombocytopenic patients due to the risk of hematoma.

Featured external sources

ASH sickle cell pain guideline.Rapid, individualized analgesia and chronic pain management in acute sickle cell pain.
ASCO antiemetics guideline update.Acute and delayed antiemetic prophylaxis according to chemotherapy emetogenic risk.
ASCO chemotherapy-induced peripheral neuropathy guideline.Dose modification in painless/painful chemotherapy neuropathy and evidence for duloxetine.

Detailed assessment

Diagnostic and decision reasoning

Clinical framework

Overview

In hematologic patients, pain and nausea are not just comfort issues; they directly affect both quality of life and adherence to treatment, and if poorly controlled, can lead the patient to discontinue treatment. The most important principle in pain management is to approach based on the cause of the pain, because different mechanisms respond to different treatments.

The painful crisis in sickle cell disease is ischemic pain caused by occlusion of small vessels by sickled erythrocytes. Pain in multiple myeloma and bone involvement is due to bone destruction and benefits from radiotherapy and skeletal-protecting treatments.

Mucositis pain arises from the direct effect of chemotherapy on the mucosa. Chemotherapy-induced peripheral neuropathy manifests as burning and tingling in a glove-and-sock distribution; this pain responds poorly to opioids and requires neuropathic agents.

Therefore, the 'there is pain, let's give opioids' approach is both insufficient and causes unnecessary side effects. There are two critical rules in managing a sickle cell painful crisis.

The first is not to delay analgesia; the goal is to give the first dose shortly after admission. Secondly, the frequent mislabeling of these patients as being 'in search of medication' is a common and harmful bias.

There is objective tissue ischemia underlying the crisis, there is no laboratory test that indicates the severity of pain, and therefore the patient's self-report should be taken as the basis. The fundamental principle in the management of nausea and vomiting is prevention.

Chemotherapy-induced nausea and vomiting is a side effect that is difficult to treat once it occurs but easy to prevent; therefore, the prophylaxis regimen is determined according to the emetogenic risk and is administered before chemotherapy. The acute phase and the delayed phase should be addressed separately; the delayed phase is often neglected and the patient experiences this period at home.

A poor experience in the first cycle leads to anticipatory nausea; since this picture is a learned response, it is resistant to antiemetic drugs, and the most effective treatment is to achieve full control in the first cycle.

Differential diagnosis and assessment

Key considerations

New pain in a hematologic patient: the progression of the disease, pathological fracture, infection, thrombosis, spinal cord compression, chemotherapy toxicity (neuropathy, mucositis), and sickle cell crisis should be distinguished.
Chest pain in a patient with sickle cell disease: acute chest syndrome, pulmonary embolism, pneumonia, rib infarction, and cardiac causes should be considered; it should not be monitored with the assumption of a pain crisis.
Back pain: vertebral fracture, spinal cord compression, epidural abscess, disc disease, and myeloma bone lesion should be differentiated; urgent evaluation is required if neurological findings are present.
Nausea in a patient receiving chemotherapy: chemotherapy-induced nausea and vomiting, constipation, drug side effects (opioid, antibiotic), hypercalcemia, electrolyte disorders, kidney and liver dysfunction, gastrointestinal obstruction, infection, and central nervous system involvement should be considered.
Neuropathic pain: chemotherapy-induced peripheral neuropathy, B12 deficiency, diabetic neuropathy, nerve compression, and amyloidosis-related neuropathy should be distinguished (relevant protocols).
Mouth pain: mucositis, herpes simplex reactivation, fungal infection (candidiasis), dental-related infection, and graft-versus-host disease should be considered.
Abdominal pain: neutropenic enterocolitis, Clostridioides difficile infection, constipation, obstruction, sickle cell crisis, and surgical emergencies should be distinguished; findings are subtle in immunosuppressed patients (relevant protocols).

Clinical decision reasoning

Why it matters

The importance of supportive care in hematology is often not sufficiently emphasized. A patient whose pain is not controlled becomes immobile, cannot sleep, cannot eat, and does not want to continue treatment; a patient whose vomiting is not controlled fears the next cycle.

Therefore, managing these side effects is not only about comfort but directly related to treatment success. Classifying pain according to its cause is the first step in this management and, in practice, is the habit that makes the most difference.

Treating pain as a single entity and merely increasing the dose of analgesics is insufficient for neuropathic pain and increases side effects; in bone pain, it misses the lasting benefit that treatments targeting the underlying destructive process (radiotherapy, skeletal protective agents) can provide. In addition, a change in the nature of the pain is often the first sign of a new complication; therefore, responding with 'pain increased, let's increase the dose' may mask a fracture, infection, or cord compression.

The painful crisis of sickle cell disease is the sharpest and most disturbing issue in this protocol because the main obstacle here is not medical but attitudinal. These patients may be labeled as 'drug-seeking' because they present frequently and require regular opioids.

The inaccuracy of this label is based on two reasons. First, there is objective tissue ischemia underlying the crisis; second, there is no laboratory test to measure the severity of this pain, so there is no criterion other than the patient's report.

The cost of delay is not just suffering: unless the pain is controlled, the patient remains immobile and does not take deep breaths, which increases the risk of acute chest syndrome. Additionally, loss of trust causes the patient to delay future visits and leads to late detection of potentially fatal complications.

Patient-specific written pain plans solve this problem both by speeding up care and eliminating debate. The principle in nausea management that 'prevention is better than treatment' is not an arbitrary choice but a physiological necessity.

Once the vomiting reflex is triggered, central mechanisms come into play and control becomes difficult; therefore, antiemetics are administered before chemotherapy. Selecting prophylaxis according to the emetogenic risk of the regimen similarly prevents two types of error: unnecessary drug burden and inadequate protection.

The most frequently neglected delayed phase is the blind spot of the system; because the patient is not in the hospital during that period, and the distress experienced is invisible until it is reported. Therefore, asking how many days nausea lasted after each cycle is the most practical way to properly adjust prophylaxis.

Anticipatory vomiting is an instructive example in which a non-drug mechanism produces a clinical outcome. The patient learns to associate vomiting with the chemotherapy setting, and after a while, the trigger is no longer the drug, but the accompanying stimuli.

This is a clinical manifestation of classical conditioning and the reason why antiemetic drugs do not show the expected effect in this scenario. The striking conclusion from this is: the adequacy of antiemetic prophylaxis in the first cycle determines not only that day but the entire treatment process.

This is one of the clearest examples showing the value of prevention.

Safety and monitoring

Complications and safety

Critical complications

Insufficient pain control leads to immobility and hypoventilation during a sickle cell crisis, increasing the risk of acute chest syndrome.
Constipation due to opioid use can create an anal fissure and a portal of infection in neutropenic patients.
Non-steroidal anti-inflammatory drugs can worsen bleeding and kidney dysfunction in thrombocytopenic patients.
Uncontrolled nausea and vomiting result in dehydration, electrolyte imbalance, nutritional deficiency, and the inability to take medications.
Anticipatory vomiting disrupts adherence to treatment and may lead to treatment delays.
Treating pain or nausea only symptomatically, without linking it to disease progression or complications, causes emergencies like spinal cord compression and hypercalcemia to be overlooked.
Regular use of paracetamol in neutropenic patients can mask fever, delaying the recognition of febrile neutropenia.
Inadequate symptom control leads the patient to discontinue treatment and lose trust in the healthcare system.

Special patient populations

Special considerations

Patients with sickle cell disease: due to recurrent crises, an individualized written pain plan should be prepared, the team should be trained against bias, and caution should be maintained regarding acute chest syndrome (relevant protocols).
Thrombocytopenic patients: non-steroidal anti-inflammatory drugs and intramuscular injections should be avoided.
Patients with renal dysfunction (myeloma, tumor lysis): the choice and doses of analgesics should be adapted according to kidney function.
Neutropenic patients: it should be kept in mind that paracetamol may mask fever, constipation should be prevented, and rectal interventions should be avoided.
Pediatric patients: age-appropriate pain scales should be used, and sedation and topical anesthesia should be planned for procedural pain (bone marrow aspiration, lumbar puncture).
Elderly patients: analgesic selection requires caution due to polypharmacy, risk of falls, renal dysfunction, and cognitive side effects.
Patients in advanced stages and receiving palliative care: symptom control is a priority, and goals should be determined together with the patient (palliative care protocol).
Pregnant patients: the choice of analgesics and antiemetics should be made according to pregnancy safety (relevant protocol).

Follow-up and reassessment

Follow-up plan

Follow-up in symptom management is an integral part of treatment and should be conducted systematically at each visit. Pain should be evaluated at each assessment in terms of intensity, quality, and impact on daily life; the patient’s self-report should be the basis.

When there is a change in the quality of pain, a new cause should be investigated, and the dose should not just be increased. Side effects in patients using analgesics (constipation, nausea, drowsiness, cognitive effects) should be assessed at each visit; in patients using opioids, it should be confirmed that laxative treatment is ongoing.

Patients receiving neuropathic pain treatment should be informed that the response develops over weeks and treatment should not be discontinued early due to lack of response. In patients receiving chemotherapy, nausea after each cycle, when it started, and how many days it lasted should be evaluated in detail; this information determines prophylaxis for the next cycle.

The delayed phase should be specifically inquired about because the patient experiences this period at home and may not report it spontaneously. Prophylaxis should be intensified in patients experiencing nausea, and if necessary, agents with different mechanisms of action should be added.

In patients who cannot take fluids and food due to vomiting, dehydration, electrolyte disturbances, and weight loss should be monitored. Patients should be provided with written information: it should be clearly explained which medication to take and when, what to do if nausea occurs at home, and under which symptoms they should seek medical attention.

It should be emphasized that conditions such as severe abdominal pain, bloody vomiting, decreased urine output, changes in consciousness, new neurological findings, and severe back pain require immediate attention. In patients with sickle cell disease, the written pain plan should be kept up-to-date, and the patient should carry this plan with them.

Throughout follow-up, it should be remembered that symptoms are managed not only with medication but holistically: sleep, nutrition, constipation, anxiety, and depression directly affect the perception of pain and nausea, and full control cannot be achieved without addressing these. The need for psychosocial support should be regularly assessed.